Austin Health - Melbourne Brain Centre, 245 Burgundy Street, Heidelberg 3084, VIC
Northeast Health - 35/47 Green St, Wangaratta, 3677, VIC
Box Hill Hospital - 8 Arnold Street, Box Hill 3128, VIC

Level 4C, Wayfinding 4C610, Royal Adelaide Hospital, Port Road, Adelaide, South Australia, 5000

NSW

Hornsby Ku-ring-gai Hospital
Rehabilitation & Aged Care Office (RACS)
Level 4, Building 60, Palmerston Road, Hornsby NSW 2077

Who can participate?
To take part in this study, you will need to meet all the following:

50 - 90 years of age
Current diagnosis of dementia (Alzheimer’s disease, Frontotemporal dementia,
Lewy body dementia, multi-infarct dementia or vascular dementia)
Experiencing agitation/aggression episodes at least twice per week
Live at-home
Have a caregiver or study partner who will be available to participate in the study

Who cannot participate?
Unfortunately, if any of the following apply to you, this study is not the right fit for you:

Have medical history of distressing psychotic symptoms (delusion and/or
hallucinations) that required psychiatric hospitalisation
History of stroke within 12 months of screening or any history of haemorrhagic
stroke
Have severe medical condition, psychiatric or neurological disease, other than
dementia
History of cancer within the past 5 years

Please note, additional eligibility criteria apply and will be discussed in a phone call
with our team.

What is involved?

If deemed eligible for the study, participation is expected to last up to 10 weeks. This
includes:

Visit 1 = Day -28 to -1 screening visit
Visit 2 = Day 1 baseline clinic visit
Visit 3 = Day 7 phone call
Visit 4 = Day 14 clinic visit
Visit 5 = Day 28 end of treatment visit
Visit 6 = Day 42 end of study visit

Participation in this research is voluntary and participants may withdraw from the
study at any time.

If you take part in the research study, there will be:

Reimbursement of costs; For out-of-pocket expenses, such as travel and parking.
Expert top-tier monitoring; Receive top-tier medical care and monitoring from experienced healthcare professionals.
Contribution to medical research; Help investigate a potential new treatment that could improve the lives of individuals with dementia-related agitation.
Free study-related medical care; Be among the first to access potential new research treatments in development.

What is dementia-related agitation?

Dementia encompasses a range of cognitive impairments including memory loss,
language difficulties, and challenges with problem-solving, all of which significantly
interfere with daily life. As the disease gets worse, people with dementia may become
agitated and may be restless or worried. Agitation may cause pacing, sleeplessness,
or aggression.

Why is this study important?
Agitation and aggression affect as many as 76% of people with dementia, impacting
the quality of life for both people with dementia and their caregivers. The findings
from this study could pave the way for improved management of agitation
associated with dementia.

Who is involved?
This study is being sponsored by Kinoxis Therapeutics Pty Ltd, a private, Australian-
based, clinical stage biotechnology company developing first-in-class therapeutics
to address the escalating demand for effective treatments for social dysfunction in
neurological and psychiatric disorders and substance use disorders.

This trial has been approved by an independent ethics committee

Ready to register? Click here to sign up/login to Evrilink and start your clinical trial journey.

Still have questions? Use the form below and one of our patient experience team members will be in touch to assist with your enquiry!